Patents Assigned to Pfizer Inc.
  • Benzisoxazole sulfonamide derivatives
    Patent number: 11492346
    Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Ring A, R1-R8, and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: November 8, 2022
    Assignees: Pfizer Inc., CTXT PTY LTD
    Inventors: Ylva Elisabet Bergman Bozikis, Michelle Ang Camerino, Pei-Pei Kung, Paul Anthony Stupple, Scott Channing Sutton
  • Chemical Compounds
    Publication number: 20220348555
    Abstract: The invention relates to pyrazole derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to HbS modulators of formula (I) or tautomers thereof, or pharmaceutically acceptable salts of said modulators or tautomers thereof, wherein X, Y, R2 and R3 are as defined in the description. HbS modulators are potentially useful in the treatment of a wide range of disorders, including sickle cell disease (SCD).
    Type: Application
    Filed: April 12, 2021
    Publication date: November 3, 2022
    Applicant: Pfizer Inc.
    Inventors: Ariamala Gopalsamy, Shawn Cabral, Agustin Casimiro-Garcia, Ming Zhu Chen, Chulho Choi, Robert Lee Dow, Olugbeminiyi Omezia Fadeyi, David Hepworth, Jayasankar Jasti, Lyn Howard Jones, Arjun Venkat Narayanan, Mihir Dineshkumar Parikh, David Walter Piotrowski, Lee Richard Roberts, Ralph Pelton Robinson, Jr., Hatice Gizem Yayla
  • Tricyclic compounds and their use as phosphodiesterase inhibitors
    Patent number: 11472805
    Abstract: The present invention is directed to compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein the substituents A, R1, R2, R3a, R3b, R4a, R4b and n are as defined herein. The inventions also directed to pharmaceutical compositions comprising the compounds, methods of treatment using the compounds and methods of preparing the compounds.
    Type: Grant
    Filed: June 9, 2016
    Date of Patent: October 18, 2022
    Assignee: PFIZER, INC.
    Inventors: Thomas Allen Chappie, Nandini Chaturbhai Patel, Patrick Robert Verhoest, Christopher John Helal, Simone Sciabola, Erik Alphie LaChapelle, Travis T. Wager, Ramalakshmi Yegna Chandrasekaran
  • Pyrazolo[1,5-a]pyrazin-4-yl derivatives
    Patent number: 11472809
    Abstract: There is a method for treating a psoriasis. A compound is administered in a therapeutically effective amount to a subject suffering therefrom. The compound has the structure or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof.
    Type: Grant
    Filed: September 8, 2020
    Date of Patent: October 18, 2022
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Alpay Dermenci, Andrew Fensome, Brian Stephen Gerstenberger, Matthew Merrill Hayward, Dafydd Rhys Owen, Stephen Wayne Wright, Li Huang Xing, Xiaojing Yang
  • composition and methods thereof
    Patent number: 11472850
    Abstract: In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B polypeptide and methods of use thereof. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup, and methods of use thereof.
    Type: Grant
    Filed: September 30, 2020
    Date of Patent: October 18, 2022
    Assignee: Pfizer Inc.
    Inventors: Annaliesa Sybil Anderson, Susan Kay Hoiseth, Kathrin Ute Jansen, Justin Keith Moran, Mark Edward Ruppen
  • Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
    Patent number: 11474112
    Abstract: The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand 1A(TL1A) The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: October 18, 2022
    Assignees: Pfizer Inc., Bristol-Myers Squibb Company
    Inventors: Robert Arch, Jun Zhang, Michelle Mader, Tetsuya Ishino, Joel Bard, William Finlay, Orla Cunningham, Ciara Reilly, Peter Brams, Brigitte Devaux, Haichun Huang, Karla Henning
  • Diacylglycerol acyl transferase 2 inhibitor
    Patent number: 11471458
    Abstract: Described herein are compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8 and R9 are defined herein, their use as diacylglycerol acyltransferase 2 (DGAT2) inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, NASH.
    Type: Grant
    Filed: October 5, 2020
    Date of Patent: October 18, 2022
    Assignee: Pfizer Inc.
    Inventors: David James Edmonds, Kevin James Filipski, Kentaro Futatsugi, Michelle Renee Garnsey, Jack Chang Hung Lee, Daniel Jonathan Smaltz
  • COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR INHIBITOR FOR TREATING CANCER
    Publication number: 20220324979
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
    Type: Application
    Filed: April 20, 2022
    Publication date: October 13, 2022
    Applicants: PFIZER INC., MERCK SHARP & DOHME CORP.
    Inventors: Jean-Francois Andre MARTINI, Jamal Christo Tarazi, Rodolfo Fleury Perini, David J. Mauro
  • 3,4-DIHYDRO-2,7-NAPHTHYRIDINE-1,6(2H,7H)-DIONES AS MEK INHIBITORS
    Publication number: 20220324861
    Abstract: The invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3 and R4 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof. The invention further relates to solid forms of 8-((2-fluoro-4-(methylthio)phenyl)amino)-2-(2-hydroxyethoxy)-7-methyl-3,4-dihydro-2,7-naphthyridine-1,6(2H,7H)-dione.
    Type: Application
    Filed: March 30, 2022
    Publication date: October 13, 2022
    Applicant: Pfizer Inc.
    Inventors: Shelley ALLEN, Patrick Michael DOERNER BARBOUR, James Francis BLAKE, Sydney Taylor BLANCHE, Mark Laurence BOYS, Wesley Dewitt CLARK, Connor James COWDREY, Joshua Ryan DAHLKE, Alex Andrew KELLUM, Ellen Margaret KNAPP, David Austin MORENO, Jacob Matthew O'LEARY, Li REN, Faith Elizabeth WITKOS
  • CDK2/4/6 Inhibitors
    Publication number: 20220324872
    Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.
    Type: Application
    Filed: June 15, 2022
    Publication date: October 13, 2022
    Applicant: Pfizer Inc.
    Inventors: Douglas Carl Behenna, Ping Chen, Kevin Daniel Freeman-Cook, Robert Louis Hoffman, Mehran Jalaie, Asako Nagata, Sajiv Krishnan Nair, Sacha Ninkovic, Martha Alicia Ornelas, Cynthia Louise Palmer, Eugene Yuanjin Rui
  • CANCER VACCINES
    Publication number: 20220323558
    Abstract: The present disclosure provides (i) isolated immunogenic TAA polypeptides (i.e., an immunogenic MUC1 polypeptides, an immunogenic MSLN polypeptides, and an immunogenic TERT polypeptides), (ii) isolated nucleic acid molecules encoding one or more immunogenic TAA polypeptides, (iii) compositions comprising an immunogenic TAA polypeptide or an isolated nucleic acid molecule encoding an immunogenic TAA polypeptide, and (iv) methods relating to uses of the polypeptides, nucleic acid molecules, and compositions.
    Type: Application
    Filed: May 13, 2021
    Publication date: October 13, 2022
    Applicant: Pfizer Inc.
    Inventors: Joseph John Binder, Paul Jason Cockle, Derek John Falconer, Siradanahalli Guru, Karin Ute Jooss, Marianne Marcela Andrea Martinic, Kenneth Nelson Wills, Helen Kim Cho
  • IMPROVEMENTS TO WASH SOLUTIONS FOR PROTEIN A CHROMATOGRAPHY IN AN ANTIBODY PURIFICATION PROCESS
    Publication number: 20220314142
    Abstract: The invention relates to a Protein A chromatography step of a purification process for a therapeutic protein, wherein a load solution including the therapeutic protein is applied onto a Protein A chromatography medium. According to the invention, a solution comprising CaCl2 is used as a wash solution for the Protein A chromatography medium for enhancing the removal of lipases, in particular phospholipase B-like 2 (PLBL2). The invention is of particular interest for the purification of CHO-expressed antibodies, such as tanezumab.
    Type: Application
    Filed: June 9, 2020
    Publication date: October 6, 2022
    Applicant: Pfizer Inc.
    Inventor: Russell Ian SHPRITZER
  • Anti-IL-2 antibodies and compositions and uses thereof
    Patent number: 11459385
    Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2R? and IL-2R?. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.
    Type: Grant
    Filed: July 9, 2020
    Date of Patent: October 4, 2022
    Assignees: The Regents of the University of California, The Board of Trustees of the Leland Stanford Junior University, Pfizer, Inc.
    Inventors: Isaac J. Rondon, Natasha Crellin, Paul Bessette, Eleonora Trotta, Jeffrey A. Bluestone, Lauren K. Ely, Kenan C. Garcia
  • Modulators of STING (Stimulator of Interferon Genes)
    Publication number: 20220306641
    Abstract: Provided herein are compounds of the general formula (I): and pharmaceutically acceptable salts thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
    Type: Application
    Filed: March 11, 2022
    Publication date: September 29, 2022
    Applicant: PFIZER INC.
    Inventors: Ketan Satish GAJIWALA, Chan Woo HUH, Mehran JALAIE, Ryan Lloyd PATMAN, Eugene Yuanjin RUI, Jianmin SUN, Martin James WYTHES
  • Nitrile-containing antiviral compounds
    Patent number: 11452711
    Abstract: The invention relates to compounds of Formula I? wherein R, R1, R2, R3, p, q and q? are as defined herein, pharmaceutical compositions comprising the compounds, methods of treating coronavirus infection such as COVID-19 in a patient by administering therapeutically effective amounts of the compounds, and methods of inhibiting or preventing replication of coronaviruses such as SARS-CoV-2 with the compounds.
    Type: Grant
    Filed: April 22, 2022
    Date of Patent: September 27, 2022
    Assignee: Pfizer Inc.
    Inventors: Dafydd Rhys Owen, Matthew Richard Reese, Matthew Forrest Sammons, Jamison Bryce Tuttle, Patrick Robert Verhoest, Qingyi Yang
  • ANTI-AVBETA8 ANTIBODIES AND COMPOSITIONS AND USES THEREOF
    Publication number: 20220289850
    Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to ?v?8 integrin. The invention includes uses, and associated methods of using the antibodies.
    Type: Application
    Filed: May 13, 2022
    Publication date: September 15, 2022
    Applicants: PFIZER INC., THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kyle Steven Niessen, Dharmaraj Samuel, Charles Ray Holst, Matthew Ross Drever, Dean Sheppard, Rosemary J. Akurst, Amha Atakilit, Dominique Meyer, Isaac J. Rondon, Joseph Dal Porto
  • Anti-proliferative agents for treating PAH
    Patent number: 11439646
    Abstract: Pulmonary hypertension and related diseases, like pulmonary arterial hypertension, can be treated by administering an effective dose of a CDK inhibitor, including palbociclib, 6-acetyl-8-cyclopentyl-5-methyl-2-{[5-(piperazin-1-yl)pyridin-2yl]amino}pyrido[2,3-d]pyrimidin-7(8H)-one, or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 4, 2020
    Date of Patent: September 13, 2022
    Assignee: Pfizer Inc.
    Inventor: Steven Martin Evans
  • Antibodies specific for CD3 and uses thereof
    Patent number: 11434292
    Abstract: The present invention provides novel antibodies that specifically bind to CD3 and uses thereof. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: September 6, 2022
    Assignee: PFIZER INC.
    Inventors: James Reasoner Apgar, Fang Jin, Madan Katragadda, Divya Mathur, Lioudmila Gennadievna Tchistiakova
  • TOLL-LIKE RECEPTOR AGONISTS
    Publication number: 20220274986
    Abstract: The present invention relates to imidazo-pyridinyl compounds, or a pharmaceutically acceptable salt thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.
    Type: Application
    Filed: May 6, 2022
    Publication date: September 1, 2022
    Applicant: Pfizer Inc.
    Inventors: Omar Ahmad, Andrew Fensome, Erik Alphie LaChapelle, Ethan Lawrence Fisher, Rayomand J. Unwalla, Jun Xiao, Lei Zhang
  • capsular polysaccharides and conjugates thereof
    Patent number: 11426456
    Abstract: The invention relates to activated Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 10A, 22F or 33F polysaccharides covalently linked to a carrier protein, processes for their preparation and immunogenic compositions and vaccines comprising them.
    Type: Grant
    Filed: October 1, 2020
    Date of Patent: August 30, 2022
    Assignee: Pfizer Inc.
    Inventors: Jianxin Gu, Rajesh Kumar Kainthan, Jin-Hwan Kim, Avvari Krishna Prasad, Yu-Ying Yang